Euro Airport Basel-Mulhouse-Freiburg
Winter flight schedule 2023/2024: an attractive range of destinations At EuroAirport, the new 2023/2024 winter flight schedule will come into effect on Sunday, October 29, 2023. Valid until March 30, 2024, it will ...
Lisbon, Portugal (ots/PRNewswire) - Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and H&T Presspart have entered in a strategic partnership to advance the development of Presspart's Sunriser© Capsule-based Dry Powder Inhaler platform. The demand for inhalable drugs that ...
Lisbon, Portugal (ots/PRNewswire) - Hovione, the specialist integrated CDMO, leader in spray drying and particle engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug delivery company, have entered a strategic partnership to expand the use of Ripple's Epidel® platform beyond ophthalmic applications. The core feature of Ripple's Epidel® technology ...
Lisbon, Portugal (ots/PRNewswire) - Hovione, the leader in spray drying and particle engineering, won the 2023 CDMO Leadership Award across all six categories – capability, compatibility, expertise, quality, reliability and service across all three groups of respondents (Big Pharma, Small Pharma, and Overall ...
Lisbon, Portugal (ots/PRNewswire) - Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years. It combines GEA´s engineering expertise with Hovione´s development and manufacturing experience and both parties commit to partner to accelerate ...
Lisbon, Portugal (ots/PRNewswire) - Hovione, the leader in spray drying and particle engineering, announced today that it has expanded its continuous manufacturing offering and services. A new state-of-the-art continuous manufacturing facility is now coming online at the Loures site in Portugal. In addition, to ...
Lisbon, Portugal (ots/PRNewswire) - Hovione and Zerion Pharma A/S (Zerion) today announced an extension of their collaboration on Zerion's Dispersome® technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility. This results in poor bioavailability and ...
Lisbon, Portugal (ots/PRNewswire) - Hovione today announced that the Board of Directors and the shareholders have approved the appointment of Dr. Jean-Luc Herbeaux as Hovione's Chief Executive Officer, effective 1st April 2022. Guy Villax, who has been Hovione's CEO for the past 25 years will now serve as a Member of the Board and shareholder. During his tenure, Hovione grew tenfold. The company currently employs 2000 ...
Lisbon (ots/PRNewswire) - Hovione, the leader in spray drying and particle engineering, announced today a strategic partnership with Zerion Pharma to market and commercialize Dispersome®, Zerion´s proprietary solubility enhancement technology platform. Zerion´s innovative Dispersome® technology builds on a new ...
Euro Airport Basel-Mulhouse-Freiburg
Lisbon (ots/PRNewswire) - Portuguese Women's Basketball achieves historic feat in sports equality The Portuguese Women's Basketball League will receive, during the next 3 years, the same sponsorship pay as the men's competition. The amount, which reaches a total investment of 3 million euros for both competitions, results from the partnership protocol signed between ...
Lisbon, Portugal (ots/PRNewswire) - Hovione, the leader in Pharmaceutical Spray Drying, today announced the launch of ASD-HIPROS, a proprietary screening service for spray dried dispersions. This platform is the most advanced and most accurate tool to identify optimal and commercially viable Amorphous Solid ...
Lisbon, Portugal (ots/PRNewswire) - Hovione today announced the signing of a partnership agreement with Ligand to significantly ramp up the production output of Captisol®. Captisol®, a Ligand product, is a chemically modified cyclodextrin proven to improve the solubility and stability of drugs. It is used in the formulation of Gilead's COVID-19 treatment Veklury® ...
Loures, Portugal (ots/PRNewswire) - Hovione announced today the appointment of Dr. Jean-Luc Herbeaux as Chief Operating Officer (COO), effective May 1st, 2020. Dr. Herbeaux held, over the past 20 years, multiple high-level leadership positions at Evonik, bringing to Hovione a proven commitment to develop a successful and globally active business. Based in Lisbon, ...
WeDo Technologies - a Mobileum Company
Lisbon, Portugal (ots/PRNewswire) - WeDo Technologies, now part of the Mobileum group, has been named a Sample Vendor in Gartner's Hype Cycle for Data Science and Machine Learning, 2019. According to the report, "data and analytics leaders should use this Hype Cycle to understand key trends and innovations, ...
Bahrain Economic Development Board (EDB)
Lisbon, Portugal (ots/PRNewswire) - The Bahrain Economic Development Board (EDB) - the investment promotion agency for the Kingdom of Bahrain in partnership with Web Summit - announced today a fast-track setup process for startups globally looking to take advantage of the business environment and startup ecosystem in Bahrain. The initiative will also enable startups to access the broader MENA region markets with the ...
EASL European Association for the study of the Liver
WeDo Technologies - a Mobileum Company
- KT (Korea Telecom) corporation and WeDo Technologies, a Mobileum company, signed a Cooperation Agreement for AI-FMS development and sales. - KT's Deep Learning (DL) based AI has been implemented and tested on WeDo's RAID FMS, the market leading fraud detection and prevention system. - This AI module, trained with KT Big Data, has proved to be highly efficient and ...
Cork, Ireland (ots/PRNewswire) - Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea. At a recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), Hovione ...
Munich (ots/PRNewswire) - - In 2019, the Edoxaban Clinical Research Programme will deliver new evidence on LIXIANA® (edoxaban) use in clinical practice. EMIT-AF/VTE is one of the first sets of data to be presented - EMIT-AF/VTE is a large observational, multicentre, multinational study on edoxaban peri-procedural ...
Munich (ots/PRNewswire) - - ELIMINATE-AF is the first set of data presented in 2019 from the Edoxaban Clinical Research Programme, which will deliver new evidence to support the use of edoxaban in clinical practice - Late-breaking data presented at EHRA 2019, the annual congress of the European Heart Rhythm ...
Lisbon (ots/PRNewswire) - Hovione has issued a bond of $50 million US dollars maturing in 2033. (Logo: https://mma.prnewswire.com/media/813604/Hovione_Logo.jpg ) The bond was arranged and subscribed by Banco BPI, S.A.. According to António Almeida, Hovione's CFO, "we issued this bond to strengthen our balance sheet as we embark in a new phase of significant capital expansion. We issued a USD denominated bond because the majority of our sales is in the USA". The bond is ...
Loures, Portugal (ots/PRNewswire) - 'One Site Shop' expands to respond to growing demands Hovione announces plan to increase production capacity in oral dosage forms in Portugal, to strengthen the integrated offering. New commercial scale equipment for blending, tableting and coating will complement existing development small scale equipment. This decision to expand follows growing customer demand since, one year ago ...
MOV.AI is developing the first industry-grade Operating System for autonomous intelligent collaborative robots for large-scale commercial deployment Lisbon, Portugal (ots/PRNewswire) - MOV.AI announced today that it raised $3M in seed funding to develop the first industry-grade O/S for autonomous intelligent collaborative robots. As such, MOV.AI is creating an ecosystem where developers, integrators and manufacturers ...
Lisbon, Portugal (ots/PRNewswire) - Symposium: S33 Novo Nordisk today announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2 diabetes who experience severe hypoglycaemia (low blood sugar levels) are at greater risk of death. The risk was four-fold higher 15 days ...
Lisbon, Portugal (ots/PRNewswire) - Oral Presentation 113 In people with type 2 diabetes, Xultophy® (insulin degludec/liraglutide) significantly reduced a number of risk factors associated with an increased risk of cardiovascular disease (CVD), compared to basal insulin.[1] According to a new post-hoc analysis presented today at the 53rd Annual Meeting of the European ...